Patrys gets second US patent for anti-cancer product PAT-LM1

Patrys Limited (ASX: PAB), a clinical stage biotechnology company is pleased to advise that it has been granted a second US patent for lead anti-cancer product PAT-LM1. 

The United States Patent Office has issued the official “Letters Patent” on a key patent in the PAT-LM1 family; US patent 8,562,995 entitled “Neoplasm specific antibodies and uses thereof”. This is the second patent to be granted in the US jurisdiction, and the third for the PAT-LM1 family. In June this year a patent covering the use of the PAT-LM1 antibody or binding fragments for the treatment or prevention of metastasis was granted in New Zealand. 

The patent claims the PAT-LM1 antibody and other variants comprising the Complementary Determining Region (CDRs) of the PAT-LM1 antibody. 

“This patent expands our intellectual property position and protects our lead product PAT-LM1. The US is a major strategic jurisdiction for therapeutic antibodies. The granting of three patents in the PAT-LM1 family further increases the value of Patrys’ patent assets, especially in the field of oncology”, said Dr. Marie Roskrow, Patrys’ Chief Executive Officer. 

Patrys has related patents pending both internationally and in the United States. 

PAT-LM1 is currently under preclinical development.